Form 8-K - Current report:
SEC Accession No. 0001193125-25-098597
Filing Date
2025-04-28
Accepted
2025-04-28 08:56:01
Documents
20
Period of Report
2025-04-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d597671d8k.htm   iXBRL 8-K 41035
2 EX-4.1 d597671dex41.htm EX-4.1 85204
3 EX-4.2 d597671dex42.htm EX-4.2 9125
4 EX-4.3 d597671dex43.htm EX-4.3 9100
5 EX-4.4 d597671dex44.htm EX-4.4 8605
6 EX-10.1 d597671dex101.htm EX-10.1 28395
7 EX-10.2 d597671dex102.htm EX-10.2 35803
8 EX-10.3 d597671dex103.htm EX-10.3 112995
  Complete submission text file 0001193125-25-098597.txt   531875

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA inab-20250427.xsd EX-101.SCH 2835
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE inab-20250427_lab.xml EX-101.LAB 18737
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inab-20250427_pre.xml EX-101.PRE 11697
22 EXTRACTED XBRL INSTANCE DOCUMENT d597671d8k_htm.xml XML 3752
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 25876273
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)